Arimeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 35,630 | 52,619 | 89,785 | 163,960 | 152,024 | 172,692 | 212,661 | 255,357 |
| Profit before tax | 2,364 | -2,474 | 3,783 | 33,223 | 15,615 | -5,996 | 6,987 | 34,672 |
| Net profit | 2,227 | -2,474 | 3,783 | 31,562 | 14,834 | -5,996 | 6,987 | 32,592 |
| Equity | 6,611 | 4,000 | 7,783 | 40,817 | 54,771 | 47,994 | 54,981 | 89,653 |
| Liabilities | 10,189 | 11,215 | 29,400 | 47,820 | 97,430 | 112,862 | 107,949 | 67,061 |
| Non-current assets | 58 | 0 | 0 | 0 | 82,012 | 76,006 | 65,710 | 55,414 |
| Current assets | 16,742 | 15,215 | 37,183 | 88,637 | 70,189 | 84,850 | 97,220 | 101,300 |
| Total assets | 16,800 | 15,215 | 37,183 | 88,637 | 152,201 | 160,856 | 162,930 | 156,714 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 35,620 | 40,974 | 48,115 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -2.0% | +47.7% | +70.6% | +82.6% | -7.3% | +13.6% | +23.1% | +20.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 13.3% | -16.3% | 10.2% | 35.6% | 9.7% | -3.7% | 4.3% | 20.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 33.7% | -61.9% | 48.6% | 77.3% | 27.1% | -12.5% | 12.7% | 36.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.3% | -4.7% | 4.2% | 19.2% | 9.8% | -3.5% | 3.3% | 12.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.6% | -4.7% | 4.2% | 20.3% | 10.3% | -3.5% | 3.3% | 13.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.5 | 2.8 | 3.8 | 1.2 | 1.8 | 2.4 | 2.0 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 17,815 | 26,310 | 44,893 | 81,980 | 76,012 | 86,346 | 106,331 | 127,679 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Arimeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-19 | 2026-08-19 | 427.86 |
| 2026-01-26 | 2026-02-02 | 427.86 |
| 2026-01-16 | 2026-01-20 | 427.86 |
| 2024-08-19 | 2024-09-09 | 0.25 |
| 2024-07-24 | 2024-08-04 | 0.25 |
| 2024-07-16 | 2024-07-23 | 0.05 |
| 2024-06-20 | 2024-07-04 | 0.05 |
| 2024-06-18 | 2024-06-19 | 229.34 |
| 2024-05-16 | 2024-06-17 | 0.05 |
| 2024-04-23 | 2024-05-06 | 0.05 |
| 2024-02-19 | 2024-02-21 | 24.27 |
| 2023-01-17 | 2023-01-22 | 397.59 |
| 2022-12-16 | 2022-12-29 | 0.09 |
Arimeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-08 | 2024-12-19 | 0.02 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Arimeda, UAB (code 302496053) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of EUR 255.4K, up 20.1% year on year and 47.9% over two years. Net profit increased to EUR 32.6K, compared with EUR 7.0K in 2024 and a loss of EUR 6.0K in 2023, showing a clear improvement in profitability. The 2025 profit margin reached 12.8%, above 3.3% in 2024 and -3.5% in 2023. At year-end 2025, total assets stood at EUR 156.7K, with equity of EUR 89.7K and liabilities of EUR 67.1K. The equity ratio was 57.2% and debt-to-equity 0.75, indicating a relatively solid balance sheet structure. Asset turnover was 1.63x, while return on equity was 36.4% and return on assets 20.8% in 2025. Revenue per employee was EUR 127.7K, and profit per employee was EUR 16.3K, reflecting improved operating efficiency.